This analysis from the COMPERA registry suggests that in medically treated patients with CTEPH, the soluble guanylate cyclase stimulator riociguat may confer a survival benefit over other PH medications https://bit.ly/3Zq3AIu.
- Held, M.
- Pausch, C.
- Huscher, D.
- Pittrow, D.
- Halank, M.
- Beckmann, S.
- Stadler, S.
- Tello, K.
- Grünig, E.
- Opitz, C.
- Delcroix, M.
- Ghofrani, H. A.
- Behr, J.
- Skride, A.
- Skowasch, D.
- Vonk-Noordegraaf, A.
- Ulrich, S.
- Klose, H.
- Rosenkranz, S.
- Olsson, K. M.
- Hoeper, M. M.
- Kopec, G.
